Cédric Lebâcle

@0x_Crash @vision_ia @grok expliques

@vision_ia C'est drole que ce mec soit devenu viral sur Reddit alors qu'il a scam beaucoup de personnes via le lancement d'un token sur pumpfun.

Nano-banana a déjà atteint LinkedIn. Nous ne pouvons plus vraiment faire confiance à nos yeux. Qu’est-ce qui est réel, qu’est-ce qui est fiction ? Les frontières commencent à s’effacer.

💥 MIBC is no longer surgery-first—oncology is rewriting the rulebook. 🩺 Surgery & Chemo (traditional backbone) Radical cystectomy ± peri-op cisplatin chemo remains standard, but morbidity & patient fitness limit its universal application. 🧬 Immunotherapy integration Neo/adjuvant ICB now proven: • CheckMate-274 → Nivolumab improved DFS & OS • AMBASSADOR → Pembrolizumab improved DFS • NIAGARA → Durvalumab peri-op improved DFS & OS 🧪 ctDNA as MRD tool • Detectable ctDNA predicts relapse post-cystectomy • IMvigor010, TOMBOLA, MODERN exploring ctDNA-guided escalation/de-escalation 🚦 → Personalised systemic therapy decisions on horizon. 🎯 ADCs + ICB combos • EV+pembro (EV-302) revolutionised metastatic setting • Now moving peri-op in VOLGA, KEYNOTE-905, KEYNOTE-B15 → Potential to boost cure rates in cisplatin-eligible & ineligible pts. 🛡️ Bladder-sparing strategies • TURBT + systemic therapy → durable CR in select pts (HCRN GU16-257, RETAIN) • Emerging risk-adapted, biomarker-driven pathways • Goal: preserve organ without compromising cure. ➡️ The next decade = convergence of powerful therapeutics + precise biomarkers + risk-adapted strategies. Not just longer survival-cure + quality of life together. 📖 JCO 2025 Review: ascopubs.org/doi/full/10.12… @ASCO @oncoalert @uro_today @theNCI #BladderCancer #Oncology #UroOnc #Immunotherapy #CancerResearch

@JCO_ASCO @siadaneshmand TAR-200 achieves the highest CR rates reported to date in BCG-unresponsive NMIBC, with durable responses and manageable safety. While single-arm and still early in follow-up, these results may redefine the bladder-sparing landscape if confirmed in phase III SunRISe trials.

TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. Co-authored by @siadaneshmand. Read the full article. brnw.ch/21wUHTZ

Phase II SunRISe-1: TAR-200 (slow drug-releasing system for gemcitabine) achieved CR in 82% of pts with BCG-unresponsive high-risk NMIBC @JCO_ASCO 🩺@siadaneshmand ❕#FDA priority review granted ascopost.com/news/august-20…

@whatsupdoc_mag L’exposition cumulative à l’anesthésie générale accélère le déclin cognitif : ≈2 ans pour les fonctions exécutives, ≈10 ans pour la vitesse de traitement, ≈26 ans pour l’attention (Stroop) après 2 h d’AG. Effet modeste mais réel, loin derrière l’âge et les comorbidités.

Anesthésie générale et chirurgie nous font-elles perdre la tête plus rapidement que prévu ? ➡️ l.whatsupdoc-lemag.fr/Cb7

@tompowles1 @KrgerMd Impressive to finally see OS benefit in MIBC with a ctDNA-guided strategy. Benefit in MRD+ while sparing MRD– patients is a paradigm shift. Still, questions remain on assay dependency, lead-time bias, and durability. Congratulations on moving the field forward.

In the future we won’t rely on pathology at surgery +/- luck to select patients for adjuvant treatment across cancers. Instead, the identification of residual disease by ctDNA/other biomarkers will be used. These data are a step towards that goal IMO. natera.com/company/news/i…

@john_damianosMD Vegetarian diets show no clear reduction in major urologic cancers (prostate, kidney, bladder). ➡️ Highlights the need for site-specific analyses — not all cancers respond equally to dietary patterns.

Vegetarians have a 12%⬇️risk of developing cancer, with different effects by cancer type: 💩21% ⬇️ colorectal cancer 👛45% ⬇️ stomach cancer 🩸25% ⬇️ blood cancers Consistent across vegetarian subgroups (vegan, lacto-ovo vegetarian, pesco-vegetarian) ajcn.nutrition.org/article/S0002-…

@dr_l_alexandre @OlivierBabeau Oubliez le chirurgien star : le bistouri de demain tiendra dans la main d’un robot.

Ce que l’opinion ne comprend pas Les robots ouvriers ne seront pas des automates stupides et spécialisés Ils seront plus intelligents qu’un polytechnicien ou un généticien Ils seront aussi meilleurs en médecine qu’un grand médecin Avec @OlivierBabeau cela nous inquiète

@jsoriamd Beyond clotting: platelets emerge as stealth couriers of tumor DNA. Exciting for #LiquidBiopsy — but the challenge will be to turn this hidden reservoir into a reliable clinical tool.

🩸 Platelets can carry tumor DNA. 🔹 Platelets – smallest yet 2nd most abundant blood cell type. 🔹New study: tumor-derived DNA found in platelets of advanced cancer patients. 🔹This cfDNA reservoir could complement plasma cfDNA, boosting detection sensitivity in low–tumor burden disease. 🔹Platelets’ ubiquity, rapid turnover & vascular contact make them ideal biosensors for cancer & genetic alterations. 🔹Findings carry broad implications for #LiquidBiopsies & precision oncology. science.org/doi/10.1126/sc…

@LauraBukavinaMD In cN+ UTUC, 56% of patients turned out to be pN0 after surgery

@LauraBukavinaMD Yet: retrospective, selection bias, limited IO/ADC, frequent cN/pN mismatch. => Surgery may help, but only in selected pts, within MDT & multimodal strategy.

Heal with steel in cN+ UTUC. 🩹🩹 🇹🇼 Nationwide cohort (n=288): RNU ↓ UTUC-specific mortality 69%→36%, 5-yr CSS 0%→39% vs. no surgery. Surgery still matters N+disease #UroOnc #UTUC nature.com/articles/s4159…

💫🌟📢 The impact of radical cystectomy (RC) on sexual health & QoL🌟💫 Presenter: @PignotG | Moderator: @CLebacle #BLADDR24 @OncoAlert @mirrorsmed 🔍 Key Points: 🟠RC impacts sexual function significantly. Yet, 41.2% of urologists avoid discussing sexual outcomes with patients. 🟠Gender gap: Women are underserved in sexual health post-RC, highlighting the need for PROMS to guide improvements. 🟠Functional recovery: Sexual-sparing strategies lead to better sexual function & urinary continence, boosting QoL. 🟠Multimodal management (incl. sex therapy, physical treatments) enhances post-op outcomes for both genders. 🛠️ Call to Action: Incorporate sexual outcomes as a surgical endpoint & empower patients with comprehensive pre-op counseling! @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @yekeduz_emre @bavilima @niklas_kluemper @nachoduranm @schmidingerRCC @DrDabestani @PignotG @lisapic @DrYukselUrun @b_szabados #BladderCancer #UroOncology #QoL #PatientCare 🧑‍⚕️👩‍⚕️

💡 Highlights from #BLADDR24: Translating Data into Practice 🚨 Moderators: @CLebacle & Fred Witjes 🔥 Practical insights into intravesical instillation for bladder cancer: @OncoAlert @mirrorsmed Efficacy Tips: Limit voiding before therapy 🚫💧 & drink fluids after 💦. Toxicity Risks: Hygiene matters! Men should void sitting 👨‍⚕️🚻. Post-op timing matters for MMC—best on surgery day ⏰🔬. 2023 Guidelines: Continuous saline irrigation 🌊 recommended for chemo-ineligible. New tools like TAR-200 & GemRIS showing promise 🌟. @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @yekeduz_emre @bavilima @niklas_kluemper @nachoduranm @schmidingerRCC @DrDabestani @PignotG @lisapic @DrYukselUrun @b_szabados #OncoTwitter #UroOncology #BladderCancer

Fantastic talks on practical surgical questions on DAY 2 of #BLADDR24 - Practical aspects of intravesical instillation by Fred Witjes - The optimal TURBT by Ben-Max de Ruiter - The impact of RC on sexual function/experience by @PignotG Moderation: @CLebacle @OncoAlert

So fun to debate my friend & colleague @b_szabados on role of ctDNA in #bladdercancer citing data from TOMBOLA IMvigor011, etc. Great moderation by @DanieleRaggi83 @tompowles1 @Uromigos @AndreaNecchi @MattGalsky @JoshMeeks @achoud72 @KilianGust @OncoAlert @mirrorsmed #BLADDR24

Day One of #BLADDR24 Presenter: Dr Cédric Lebâcle Debate: Are we ready to de-intensify treatment and surveillance in low-grade NMIBC? PRO and CON PRO: The debate on whether we are ready to de-intensify treatment and surveillance in low-grade non-muscle invasive bladder cancer (NMIBC) sees the "pro" side arguing that an adapted de-intensification strategy offers several benefits. These include minimizing the risks and side effects of interventions, reducing patient anxiety, and easing the treatment burden, all while ensuring safe and effective care. From a global perspective, this approach can help decrease unnecessary procedures in low-risk NMIBC patients without compromising cancer control, maintaining oncological outcomes while improving overall patient quality of life. @UrsulaVogl @PGrivasMDPhD @achoud72 @ZilliThomas @fabioturco92 @nataliagandur @yekeduz_emre @bavilima @niklas_kluemper @DrYukselUrun @mirrorsmed @bkonety @evacomperat @Achard_Verane @daandm @mdesantis234 @KilianGust @bkonety @CLebacle @LAUrology_NL @Renate_Pichler @DanieleRaggi83 @CelenaBergdahl @bm_deruiter Still time to Register: buff.ly/3Z4aEt3

Big AI discovered a new structural class of antibiotics! The last one took 38 years with multiple compounds effective vs methicillin-resistant Staph aureus, without toxicity. Article: nature.com/articles/s4158…

@VerhoestGregory @UrologieRennes @CHURennes @WorldBladderCan @BladderCancerUS @CancerVessie Si on souhaite mettre en évidence 10% de complications en moins, il faudrait 392 patients par groupe. Partant ?

A big day for bladder ca patients @US_FDA. Massive team effort. Platinum based chemo superseded at last. EV/pembro will transform the lives of many pts with this difficult disease. Still lots to do but it’s a pretty good day and worth pausing for a moment. bit.ly/3GLntQn